GPCR vs. LEGN, ELAN, CYTK, NUVL, GRFS, VKTX, AXSM, TGTX, KRYS, and OGN
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Krystal Biotech (KRYS), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.
Structure Therapeutics vs.
Legend Biotech (NASDAQ:LEGN) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Legend Biotech currently has a consensus price target of $80.62, suggesting a potential upside of 146.83%. Structure Therapeutics has a consensus price target of $81.29, suggesting a potential upside of 200.39%. Given Structure Therapeutics' higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Legend Biotech.
Structure Therapeutics has lower revenue, but higher earnings than Legend Biotech. Structure Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
Legend Biotech received 54 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 88.24% of users gave Structure Therapeutics an outperform vote while only 71.79% of users gave Legend Biotech an outperform vote.
In the previous week, Legend Biotech had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 6 mentions for Legend Biotech and 1 mentions for Structure Therapeutics. Legend Biotech's average media sentiment score of 0.57 beat Structure Therapeutics' score of 0.13 indicating that Legend Biotech is being referred to more favorably in the media.
Structure Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Structure Therapeutics' return on equity of -16.37% beat Legend Biotech's return on equity.
Legend Biotech has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -2.78, indicating that its share price is 378% less volatile than the S&P 500.
Summary
Structure Therapeutics beats Legend Biotech on 9 of the 16 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GPCR) was last updated on 1/20/2025 by MarketBeat.com Staff
Free GPCR Stock Alerts